Free Guide
GLP-1 Insurance Coverage Guide
Navigating insurance for GLP-1 medications is one of the most frustrating parts of the journey. This guide breaks down what coverage looks like across every major plan type — and how to fight for approval if you're denied.
NEW: Medicare GLP-1 Bridge Program — $50/Month Launched July 1, 2026
Medicare is now covering Wegovy, Zepbound (KwikPen), and Foundayo for weight loss at a fixed $50/month copay for eligible Part D enrollees — no matter where you are in your Part D coverage phase. The program runs through December 2027.
Full Bridge Program Guide — Who Qualifies & How to Sign UpCoverage changes frequently. Insurance rules, formularies, and PA criteria are updated regularly. Always verify current coverage with your specific plan. This guide is updated as of July 2026 and is for informational purposes only — not insurance or legal advice.
$800–$1,350
without coverage
$0–$50/mo
typical copay when approved
$573/mo
Lilly Zepbound savings card
1–10 days
business days, varies by plan
Coverage by Plan Type
Commercial Insurance (Employer-Sponsored)
Coverage depends entirely on your specific plan and employer. Roughly 40–50% of large employer plans now cover GLP-1 weight loss medications, but criteria are strict.
Coverage Details
- BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (T2D, hypertension, sleep apnea, dyslipidemia, cardiovascular disease)
- Prior authorization almost always required before the first fill
- Documentation of 3–6 months of failed lifestyle intervention (diet + exercise) often required
- Ongoing coverage typically requires demonstrated weight loss milestones (varies by plan — often 5% in first 3–6 months)
- Coverage for Ozempic/Mounjaro as diabetes medications is more consistent than weight management coverage
- Zepbound and Wegovy specifically for chronic weight management — fewer plans cover these than their diabetes-indication counterparts
Pro Tip
Call the member services number on your insurance card and ask specifically about 'anti-obesity medications' or 'GLP-1 receptor agonists for chronic weight management.' Get the PA criteria in writing.
Medicare — GLP-1 Bridge Program Active
The Medicare GLP-1 Bridge Program launched July 1, 2026. Eligible Part D enrollees now access Wegovy, Zepbound (KwikPen), and Foundayo for a fixed $50/month copay through December 2027.
Coverage Details
- Bridge Program runs July 1, 2026 – December 31, 2027 — all Part D plans (standalone PDP and MA-PD) must participate
- Covered drugs: Wegovy (semaglutide, all forms), Zepbound KwikPen (tirzepatide), Foundayo (orforglipron, oral tablet) — for weight management only
- NOT covered under Bridge: Ozempic, Mounjaro, Saxenda, or compounded GLP-1 medications
- BMI eligibility: ≥ 35 (any); ≥ 30 with heart failure, hypertension, or CKD; ≥ 27 with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease
- Type 2 Diabetes patients are excluded from the Bridge — but may already have coverage through the diabetes indication for Ozempic or Mounjaro
- Important: the $50 copay does NOT count toward your Part D deductible or $2,100 out-of-pocket maximum; Extra Help / Low-Income Subsidy does not apply
- No separate enrollment needed — talk to your doctor, get a prescription for a Bridge-eligible drug, doctor submits a prior authorization through CMS
Pro Tip
Call your doctor today and ask specifically about 'the Medicare GLP-1 Bridge Program.' Reference Wegovy, Zepbound KwikPen, or Foundayo for weight management. Your doctor submits a CMS prior authorization — you do not fill out any paperwork yourself.
Medicaid
Coverage varies dramatically by state. Some states cover GLP-1 medications broadly; others exclude them entirely.
Coverage Details
- Each state administers Medicaid independently — coverage rules differ across all 50 states
- Some states (e.g., California, Massachusetts) have added GLP-1 weight management coverage with prior authorization
- Other states only cover GLP-1s for patients with Type 2 Diabetes diagnosis
- Many states cover Ozempic and Mounjaro for diabetes but not Wegovy or Zepbound for weight management
- Income and eligibility requirements for Medicaid itself vary — expanded Medicaid states have broader population coverage
- Contact your state's Medicaid program directly for current formulary status
Pro Tip
Search '[your state] Medicaid preferred drug list' to see your state's current formulary. This is updated quarterly and is the most accurate source.
Federal Employee Health Benefits (FEHB)
Federal employees often have some of the better GLP-1 coverage through FEHB plans, though it varies by carrier.
Coverage Details
- Major FEHB carriers (BCBS Federal, Aetna, United) have added weight management GLP-1 coverage in recent benefit years
- Blue Cross Blue Shield Federal Employee Program (FEP) has covered Wegovy and Zepbound with prior authorization and BMI requirements
- OPM (Office of Personnel Management) has encouraged carriers to expand coverage
- Standard prior authorization criteria apply: BMI requirements, comorbidity documentation, lifestyle intervention history
- Some FEHB plans require enrollment in a weight management program concurrently
- Coverage varies between High Option, Standard Option, and Basic Option plans even within the same carrier
Pro Tip
During Open Season, compare FEHB plans specifically on their GLP-1 coverage — use the OPM plan comparison tool and look at the formulary for 'semaglutide' and 'tirzepatide.'
VA & TRICARE (Military/Veterans)
Both the VA and TRICARE have pathways for GLP-1 coverage, with specific eligibility criteria.
Coverage Details
- VA covers semaglutide (Ozempic) for Type 2 Diabetes and, in some facilities, Wegovy for weight management
- VA access depends on availability through VA formulary and individual VA medical center decisions
- TRICARE covers FDA-approved weight management medications including Wegovy and Zepbound with prior authorization
- TRICARE requires documented failure of behavioral weight loss program before approval
- Active duty service members may have different access pathways than retirees and dependents
- Contact your VA provider or TRICARE regional contractor for current formulary status
Pro Tip
VA patients should ask their primary care provider about the MOVE! program — participation in this structured weight management program often supports GLP-1 authorization requests.
The Prior Authorization Process
Prior authorization (PA) is required by nearly every plan that covers GLP-1 weight management medications. Here's how it works step by step.
Get a prescription
Your provider writes a prescription for a GLP-1 medication with the appropriate diagnosis code (E66.9 for obesity, E11.x for Type 2 Diabetes, etc.). The diagnosis code matters — some medications are only covered under certain diagnoses.
Pharmacy flags it for PA
When you submit the prescription to the pharmacy, it will typically come back as 'prior authorization required.' The pharmacy sends a PA request to your insurance or notifies your provider's office to initiate one.
Provider submits clinical documentation
Your doctor's office submits PA paperwork including BMI, weight history, comorbidity diagnoses, previous weight loss attempts, and sometimes a letter of medical necessity. Strong documentation significantly improves approval rates.
Insurance reviews (1–10 business days)
The insurer's pharmacy benefits manager (PBM) reviews the documentation against their coverage criteria. Some plans allow peer-to-peer reviews where your doctor can speak directly with the PBM's medical reviewer.
Approval or denial
You'll receive an approval (often 90 or 180 days, then renewed) or a denial with specific reasons. Denials must include the exact criteria you didn't meet and information about your appeal rights.
If denied — appeal
File a formal appeal immediately. Include additional documentation, peer-reviewed studies on the medication, and if possible, a letter from your cardiologist or endocrinologist. First-level appeals have reasonable success rates. If denied again, request an external independent review.
Common Denial Reasons — and How to Fight Them
Don't accept a denial at face value. Most initial PA denials are overturned on appeal with the right documentation.
Insufficient documentation of lifestyle intervention
Get a letter from your provider documenting diet and exercise counseling dates and outcomes. Even 3 months of documented attempts helps.
BMI doesn't meet threshold
Ensure your BMI is calculated and documented correctly. If you have comorbidities (hypertension, sleep apnea), the threshold is BMI ≥27, not ≥30.
Drug is 'not medically necessary'
Request a peer-to-peer review between your doctor and the insurance medical reviewer. Ask your provider to emphasize cardiovascular and metabolic risk reduction.
Step therapy required
Insurance may require trying a lower-tier medication first. Ask your provider if there's a medical exception basis for skipping step therapy (often: prior failure of step therapy drug).
Weight loss indication not covered
If you have Type 2 Diabetes, ask about Ozempic or Mounjaro under the diabetes indication instead. Different formulary benefit, often better coverage.
Cost Reduction Strategies
Use diagnosis codes strategically
Ozempic (for T2D) and Wegovy (for obesity + cardiovascular risk) may have different coverage tiers. Your provider should choose the most accurate diagnosis that supports coverage.
Document everything
Keep copies of all PA submissions, denials, and appeal letters. Track dates. Insurance companies have deadlines for appeals that vary by state.
Ask about manufacturer programs
Novo Nordisk (NovoCare) and Eli Lilly both have patient assistance programs and savings cards for qualifying patients. These can dramatically reduce out-of-pocket costs.
Consider GoodRx for diabetes formulations
Ozempic and Mounjaro (diabetes-indication) are sometimes available at significantly reduced prices through GoodRx or similar discount programs at retail pharmacies.
Check your Explanation of Benefits (EOB)
After any claim, review your EOB for billing errors. Incorrect procedure codes or diagnosis codes are surprisingly common and can affect coverage determinations.
Manufacturer Assistance Programs
Novo Nordisk — NovoCare
Patient assistance program for Ozempic and Wegovy. Qualifying uninsured or underinsured patients may receive medications at significantly reduced or no cost.
- Income-based eligibility
- Wegovy savings offer — $0 for 13 weeks (insured patients)
- NovoCare helpline: 1-833-NOVO-411
Eli Lilly — LillyDirect
Lilly's direct-to-patient telehealth and pharmacy program for Zepbound. Savings card for eligible insured patients; patient assistance for uninsured/underinsured.
- Zepbound savings card — as low as $550/mo for eligible patients
- Single-dose vials direct from Lilly at reduced pricing
- Lilly Cares Foundation for qualifying low-income patients
While You Navigate Insurance…
Getting approved takes time. In the meantime, maximize the effectiveness of whatever access to GLP-1 medications you have — or explore whether compounded options make sense for your situation.